During the past 20 years, hundreds of thousands of women with breast cancer have taken the drug Herceptin, typically for a year or more. The medicine, used to treat an aggressive form of the disease, ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III ...
– At three years, 88.3 percent of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0 percent treated with ...
Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin ...
Cardiotoxicity is an important adverse effect of trastuzumab in the treatment of breast cancer. Particularly in the adjuvant setting, a high risk of cardiotoxicity is unacceptable, since the ...
EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union (EU) for the treatment of ...
High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment. High tumor infiltrating lymphocytes (TILs) in ...
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
Trastuzumab combined with gemcitabine-cisplatin was safe and demonstrated significant efficacy in terms of improved response to chemotherapy and prolonged survival. The presence of TP53 mutations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback